Therapeutic nanoparticles must rapidly penetrate the mucus secretions lining the surfaces of
the respiratory, gastrointestinal and cervicovaginal tracts to efficiently reach the underlying …

Nanoparticles that readily penetrate mucosal layers are desirable for a variety of biomedical
applications. Nevertheless, most nanoparticles tend to be immobilized in mucus via steric …

Mucosal drug delivery nanotechnologies are limited by the mucus barrier that protects
nearly all epithelial surfaces not covered with skin. Most polymeric nanoparticles, including …

Nanoparticles larger than the reported mesh-pore size range (10–200 nm) in mucus have
been thought to be much too large to undergo rapid diffusional transport through mucus …

Aim: We previously reported that nanoparticles (NPs) coated with 10 kDa PEG were
mucoadhesive. Here, we demonstrate that by increasing the surface density, PEG with …

Achieving sustained drug delivery to mucosal surfaces is a major challenge due to the
presence of the protective mucus layer that serves to trap and rapidly remove foreign …

Protective mucus coatings typically trap and rapidly remove foreign particles from the eyes,
gastrointestinal tract, airways, nasopharynx, and female reproductive tract, thereby strongly …

Mucus secretions typically protect exposed surfaces of the eyes and respiratory,
gastrointestinal and female reproductive tracts from foreign entities, including pathogens …

The viscoelastic mucus secretions coating exposed organs such as the lung airways and the
female reproductive tract can trap and quickly eliminate not only foreign pathogens and …

Mucus secretions coating entry points to the human body that are not covered by skin
efficiently trap and clear conventional drug carriers, limiting controlled drug delivery at …